Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.
Koelewijn
C
C
Department of Gastroenterology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Schrijvers
A
A
Oldenburg
B
B
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D015331:Cohort Studies; D003424:Crohn Disease / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D016527:Drug Costs; D005060:Europe / Q000453:epidemiology; D005765:Gastrointestinal Agents / Q000191:economics / Q000627:therapeutic use*; D006295:Health Resources / Q000191:economics / Q000706:statistics & numerical data*; D006801:Humans; D000069285:Infliximab; D009656:North America / Q000453:epidemiology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab